have uncovered hundreds of loci mediating risk 1,2 . These associations are preferen-14 tially located in non-coding DNA regions 3,4 and in particular to tissue-specific DNase 15 I hypersensitivity sites (DHS) 5,6 . Whilst these analyses clearly demonstrate the over-16 all enrichment of disease risk alleles on gene regulatory regions, they are not designed 17 to identify individual regulatory regions mediating risk or the genes under their con-18 trol, and thus uncover the specific molecular events driving disease risk. To do so we 19 have departed from standard practice by identifying regulatory regions which replicate 20 across samples, and connect them to the genes they control through robust re-analysis 21 of public data. We find substantial evidence of regulatory potential in 132/301 (44%) 22 risk loci across nine autoimmune and inflammatory diseases, and are able to prioritize 23 a single gene in 104/132 (79%) of these. Thus, we are able to generate testable mech-24 anistic hypotheses of the molecular changes that drive disease risk.
genes identified (Table 3) . We found that, whilst the overlap between lead variants was low, we 23 could more often identify the same DHS clusters and prioritize the same genes (Fisher exact test 24 between proportion of lead SNPs and prioritized genes p = 0.014). We found the rate of prioritized 25 gene overlap is correlated to linkage disequilibrium between lead variants (Supplementary Figure   26 10), suggesting that though GWAS may not identify the same variant representing a shared associ-27 ation, shared effects can clearly be identified by considering the likely functional effects in a locus. 28 These observations hold true when we only consider the 17 loci harboring two disease associations 29 ( Supplementary Table 3 and Supplementary Figure 10 ), indicating our conclusions are not based on 30 biases in a minority of loci harboring many associations. Thus, our approach can uncover biological 31 pleiotropy 30 across diseases even when the identity of the causal variant remains unknown, beyond 32 the comparison of credible interval sets. 33 34 We have described an approach to detect gene regulatory regions driving disease risk and through 35 them, the genes likely to mediate pathogenesis, through robust re-analysis of public data. We find 36 substantial evidence of regulatory potential in a substantial proportion (44%) of loci across nine 37 AID, and resolve these to a single gene in 104/132 (79%) controlled by regulatory regions active in 38 immune cells. In the majority of loci we examine, we do not prioritize the gene closest to the maxi-39 mally associated marker. This suggests that risk-mediating regulatory elements act at considerable 40 distances, either by influencing the overall transcriptional landscape of the region or by acting on in-41 dividual genes at a distance through DNA looping events mediated by DNA-protein interactions 31 . 42 These competing explanations make different predictions: the former implies many genes will be 43 controlled by the risk-mediating regulator, whereas the latter predicts a limited number of targets. 44 As we are able to prioritize a single gene in the majority of cases, our results strongly suggest that 45 risk is mediated by changes to specific gene regulatory programs affecting particular genes, which 46 must be involved in pathogenesis. More broadly, the observation that most common, complex disease risk aggregates in gene regu-1 latory regions 3,4,5 has made the translation of genetic association results into molecular and cellular 2 mechanisms challenging. Fine-mapping is limited in resolution by linkage disequilibrium, making 3 association data alone insufficient to identify a causal variant driving risk in a locus. For exam-4 ple, in a recent Immunochip study of multiple sclerosis 32 , we were able to reduce 14/66 (21%) 5 Immunochip regions to 90% credible interval sets of fewer than 15 variants, and 5/66 to fewer than 6 5 variants, though increases in sample size will raise the resolution of these approaches 14 . Unlike 7 coding variants, inferring function of non-coding polymorphisms remains challenging, though efforts 8 to integrate functional genomics and population genetics data into composite functional scores 33,34 9 or integrating genetic and epigenetic data 11 are gaining some traction on this problem. Our own 10 work complements these efforts by focusing on identifying individual regulators and the genes they 11 control to generate testable hypotheses of the molecular basis of disease mechanism. ple, we called 150bp DNase I hypersensitive sites (DHS) passing a 1% FDR threshold 17 . We found 19 56 tissues with at least two replicates, which our statistical replication design requires, and limited 20 our analysis to these. Where more than two replicates were available, we chose the two replicates 21 with the smallest Jaccard distance between their DHS peaks positions on the genome.
23
To identify corresponding DHS across samples, we calculated the overlap between neighboring 24 peaks across the 112 replicate samples as:
where, O i,j is the number of base pairs shared by DHS i and j, and l i and l j are the length of DHS 26 i and j respectively. We then grouped DHS with a graph-based approach, the Markov Clustering 27 Algorithm 35 (MCL) using the default parameters, and defined the coordinates of a DHS cluster as 28 the extreme positions covered by DHS peaks included in that cluster. Finally, we define each clus-29 ter as accessible in a sample if we observe at least one DHS peak within its boundaries in that sample.
31
Both peak calling and MCL clustering are naive to sample labels, so we can test for evidence that 32 DHS clusters replicate in this analysis. We expect that DHS clusters representing true regulatory 33 regions should be consistently accessible or unaccessible in replicate samples. We can thus calculate 34 a replication statistic for DHS cluster d as:
where n 1 is the number of cell types where DHS cluster d is active in both replicates; n 2 is the 36 number of cell types where the cluster is active in only one of the two replicates; and n 3 is the 37 number of cell types where the cluster is inactive in both replicates. For N = 56 tissues in our data 38 a = n 1 /N , b = n 2 /N and c = n 3 /N . Further, if r is the number of samples where DHS cluster is 39 active, then p = r/(2 × N ), and q is 1 − p. Note that we distinguish between the number of cell 
16
From this null, we computed empirical P-values of significance of correlation between DHS cluster 17 d and gene g as
g is the Wilcoxon rank sum test statistics between DHS cluster d and gene g, and |.| denotes 19 the number of events satisfying the enclosed criterion. This formulation accounts for the two-sided 20 test. We used a permutation-based approach to assess the significance of the correlation between 21 DHS clusters and gene expression using a random set of 2000 genes from across the genome. We 22 correlated each random gene to each DHS cluster, and compared test genes against this expected 23 distribution of correlation coefficients to obtain an empirical P value (Supplementary Figure 12 ).
25
We next calculated the proportion of posterior probability of association transmitted from DHS 26 cluster d to gene g as
where χ 2 d,g i is the chi-squared test statistic corresponding to the empirical correlation P value for 28 DHS cluster d and gene g i . From this we computed the total posterior transmitted from DHS cluster 29 d to gene g as
For each gene, we then sum over all DHS clusters D to obtain the overall posterior probability of 31 association:
In practice, if P d,g > 0.25 we set β d,g to zero to control noise from small values (Supplementary SNPs from all diseases as a joint set. We found this enrichment to be consistent across minor allele 6 frequency bins (Supplementary Figure 14) . The accessibility of these DHS clusters is correlated to expression levels of several genes in the region. By partitioning the posterior probability of association attributable to each DHS cluster by the strength of this correlation, we find that 48.2% can be attributed to CD58, with the next-highest scoring genes MAB21L3 and CD2 being attributed 27.2% and 12% respectively. (D) Note that the correlation between DHS1 accessibility and CD58 expression level is particularly strong across tissues. (C) inflammatory bowel disease; (D) multiple sclerosis; and (E) type 1 diabetes localizes over the coding region of BACH2. However, we can attribute the majority of regulatory potential to a single DHS cluster (DHS12) in (A), (D) and (E), which is correlated to the expression of MDN1, encoded > 500kb from the most associated variant. We find a much weaker correlation to BACH2 expression. In celiac disease, DHS12 receives the second-highest ρ in the locus, but GABBR2 receives a higher overall posterior (γ M DN 1 = 0.074 and γ GABBR2 = 0.134, respectively). In contrast, the strongest IBD posterior is attributed to DHS9, which implicates MAP3K7. (F) These differences are consistent with differing LD levels between the most associated SNPs for each disease in the region.
